MV Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

MV Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$635	Buy	19 +1	+6%	+$25	﹤0.01%	992
2026 Q1	$378	Sell	18 -10	-36%	-$225	﹤0.01%	1010
2025 Q4	$644	Sell	28 -40	-59%	-$1.31K	﹤0.01%	887
2025 Q3	$2.05K	Buy	68 +52	+325%	+$1.56K	﹤0.01%	705
2025 Q2	$582	Buy	16 +12	+300%	+$433	﹤0.01%	833
2025 Q1	$145	Sell	4 -4	-50%	-$166	﹤0.01%	955
2024 Q4	$337	Buy	8 +7	+700%	+$347	﹤0.01%	852
2024 Q3	$56	Sell	1 -1	-50%	-$51	﹤0.01%	1011
2024 Q2	$83	Buy	2 +1	+100%	+$43	﹤0.01%	915
2024 Q1	$47	Buy	+1	New	+$47	﹤0.01%	820

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

MV Capital Management's RARE Position: Q2 2026 in Review

MV Capital Management increased its Ultragenyx Pharmaceutical (RARE) stake by 5.6% in Q2 2026, buying an estimated $25 and bringing the position to 19 shares worth $635. The position accounts for ﹤0.01% of the portfolio, ranked #992.

MV Capital Management first reported a position in RARE in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.05K in Q3 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

MV Capital Management held 19 shares of Ultragenyx Pharmaceutical worth $635 as of Q2 2026.
MV Capital Management bought 1 Ultragenyx Pharmaceutical share in Q2 2026, an estimated $25.
Ultragenyx Pharmaceutical made up ﹤0.01% of MV Capital Management's portfolio in Q2 2026, its #992 holding.
MV Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and has held it in 10 quarters since.
MV Capital Management's Ultragenyx Pharmaceutical position peaked at $2.05K in Q3 2025.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on MV Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.